Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Consumer stocks lead the gains
Tue, 25 Feb 11:30 am

After opening firm, the Indian indices are above the dotted line in the morning session. Apart from metal and energy stocks, most of the sectoral indices are trading in the green led by consumer stocks from the FMCG sector.

The BSE-Sensex is trading up 50 points and the NSE-Nifty is trading up 17 points. The BSE Mid Cap index is trading up 0.5% and the BSE Small Cap index is trading up 0.4%. The rupee is trading at 61.99 to the US dollar.

Textile stocks are trading mixed today. While Eastern Silk and Arvind are leading the gainers, Vardhman Textiles and Alok Industries are leading the losers. India's leading innerwear textile firm, Page Industries, has announced its 3QFY14 results. The company has reported 39% YoY growth in sales on the back of good volumes. The operating margin improved by 0.6% YoY for the quarter to come in at 19% despite higher raw material costs (as percentage of sales). Higher interest costs and depreciation expenses did not dampen the bottomline performance. Driven by the strong operating performance, the net profit grew by 36.2% YoY. Page Industries is trading up 0.2% today.

Most pharma stocks are currently trading firm. While Aurobindo Pharma and Orchid Chemicals are leading the gainers, Piramal Enterprises and Dr. Reddy's Lab are leading the losses. As per the BSE announcement filing, Japan's Daiichi Sankyo owned Indian drug maker Ranbaxy has voluntarily suspended drug ingredients shipments from two of its manufacturing plants. Namely, the Toansa and Dewas plants have suspended all shipments as the company is examining processes and controls. Both plants are currently banned from shipping products to the US following US FDA ban on quality concerns. The suspension will hit its supplies in other markets including Europe and India. The voluntary decision has been taken as a precautionary measure and it plans to resume the shipments after reassurance of the processes and controls. Ranbaxy has not given the financial details with respect to impact of the suspension. Further the company has set up committee with primary role to oversee the problems of manufacturing and quality operations, systems, organization and integrity. The stock of Ranbaxy is trading higher by 0.9% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Consumer stocks lead the gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.